Cogent Biosciences (COGT) Profit After Tax (2017 - 2026)

Cogent Biosciences (COGT) has reported Profit After Tax for 10 consecutive years, with -$97.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 34.71% year-over-year to -$97.4 million; the TTM figure through Mar 2026 stood at -$354.3 million (down 72.59% YoY), while the FY2025 annual figure was -$328.9 million, down 28.55% from the prior year.
• Profit After Tax advanced to -$97.4 million in Q1 2026 per COGT's latest filing, from -$102.5 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$3.4 million in Q4 2024 and bottomed at -$102.5 million in Q4 2025.
• Historically, Profit After Tax has averaged -$54.1 million across 5 years, with a median of -$58.3 million in 2024.
• Annual changes were most pronounced in 2023 — Profit After Tax soared 72.16% — and 2025, when it sank 2877.92%.
• Cogent Biosciences' Profit After Tax stood at -$39.5 million in 2022, then retreated by 14.84% to -$45.3 million in 2023, then jumped by 92.4% to -$3.4 million in 2024, then tumbled by 2877.92% to -$102.5 million in 2025, then climbed by 5.02% to -$97.4 million in 2026.
• Business Quant data shows COGT's Profit After Tax at -$97.4 million in Q1 2026, -$102.5 million in Q4 2025, and -$80.9 million in Q3 2025.